Mankhwala Omwe Anayambika Koyambirira kwa Chithandizo cha Khansa ya M'mawere Amapereka Chiyembekezo

Padziko lonse lapansi, R&D pa khansa ya m'mawere m'mitundu yonse yakhala ikukula mwachangu pazaka zingapo zapitazi ndipo ipitilira zaka zikubwerazi. Khansara ya m'mawere ndi khansa yachiwiri yofala kwambiri padziko lonse lapansi komanso khansa yofala kwambiri mwa amayi padziko lonse lapansi.

Khansara ya m'mawere ya Human epidermal growth factor receptor 2-positive (HER2+) imapanga pafupifupi 20% ya anthu omwe ali ndi khansa ya m'mawere ndipo mbiri yakale imakhudzana ndi kusazindikira bwino popanda chithandizo chamankhwala. Kuzindikira kuti kuyambitsa mankhwala omwe amatsata HER2 koyambirira munjira yoyendetsera matenda kumatha kupititsa patsogolo moyo wopanda matenda (DFS) kwapanga msika wawukulu wamankhwala oyendetsedwa ndi HER2. Masiku ano, odwala khansa ya m'mawere a HER2+ akukhala ndi moyo wautali ndi matenda awo, chifukwa cha njira zoyendetsera matenda zomwe zakhazikitsidwa pogwiritsa ntchito ma regimens. Malinga ndi Stats Market Research msika wa HER2+ ukuyembekezeka kukula mpaka $12.1B pofika 2030, pa Compound Annual Growth Rate (CAGR) ya 1.5%. Lipoti lochokera ku Mordor Intelligence linawonjezera kuti msika wochizira khansa ya m'mawere ukuyembekezeka kukula pa CAGR ya 8.3% panthawi yolosera, 2022-2027. 

Lipotilo lidati: "Chifukwa cha kufalikira kwa COVID-19, msika wakumana ndi zovuta pang'ono chifukwa chakuchedwa kwa matenda, kusowa kwa mankhwala, komanso kusapezeka kwa akatswiri azachipatala. Mwachitsanzo, malinga ndi nkhani yomwe idasindikizidwa mu JAMA Network mu Ogasiti 2020, panali kuchepa kwakukulu kwa matenda a khansa ya m'mawere (mofika 51.8%) ku United States kuyambira pa Marichi 1, 2020, mpaka Epulo 18, 2020. , kuchedwa kwa matenda a khansa ya m'mawere kwakhudzanso chithandizo chofanana. Chifukwa chake, mliri wa COVID-19 wasokoneza msika wamankhwala a khansa ya m'mawere mu gawo lake loyamba. Komabe, msika ukuyembekezeka kuchulukirachulukira mzaka zikubwerazi pomwe chithandizo chikuyambiranso padziko lonse lapansi. ” Makampani omwe akugwira ntchito pa biotech ndi pharma m'misika sabata ino akuphatikizapo Oncolytics Biotech® Inc., Clovis Oncology, Inc., Belite Bio Inc., Endo International plc, Pfizer Inc.

Kafukufuku wa Msika wa Stats anapitiliza kuti: "Kupitilira apo, zomwe zikupangitsa kukula kwa msika ndikuchulukirachulukira komanso kuchuluka kwa khansa ya m'mawere padziko lonse lapansi, kuchulukitsa ndalama pakufufuza ndi chitukuko, komanso kupita patsogolo kwa biology ya khansa ndi zamankhwala zomwe zimalimbikitsa chitukuko chamankhwala. Kuchulukirachulukira komanso kuchuluka kwa khansa ya m'mawere padziko lonse lapansi ndichinthu chachikulu chomwe chikuyendetsa kukula kwa msika. Ku North America, United States ikuyembekezeka kulamulira msika wonse panthawi yonse yolosera. Zomwe zikupangitsa kukula kwa msika ndikuchulukirachulukira kwa khansa ya m'mawere mdziko muno komanso chidziwitso chokhudzana ndi khansa ya m'mawere komanso kukwera kwazinthu zomwe zatulutsidwa. ”

Oncolytics Biotech® ndi SOLTI Present New Clinical Biomarker Data Kuwonetsa Kuthekera kwa Pelareorep Kupititsa patsogolo Kuzindikira kwa Odwala Khansa Yam'mawere pa Msonkhano wa ESMO Breast Cancer Meeting - Oncolytics Biotech® ndi SOLTI-Innovative Cancer Research lero yalengeza zatsopano zamankhwala za biomarker zomwe zikuwonetsa pelarepeupeutic zotsatira Kuletsa, komanso kuthekera kopititsa patsogolo kawonedwe ka odwala omwe ali ndi khansa ya m'mawere ya HR+/HER2-. Zambiri, zomwe zawonetsedwa pazithunzi pa Msonkhano wa 2022 European Society for Medical Oncology (ESMO) Breast Cancer Meeting, zimachokera kumagulu 1 ndi 2 a kafukufuku wamwayi wa AWARE-1 ​​pa odwala khansa ya m'mawere oyambilira.

Odwala omwe ali m'magulu awiri oyambirira a AWARE-1 ​​amathandizidwa ndi pelareorep ndi aromatase inhibitor letrozole popanda (cohort 1), kapena ndi (cohort 2), PD-L1 checkpoint inhibitor atezolizumab pafupifupi masiku 21 asanayambe opaleshoni ya zotupa zawo. Cohorts 1 ndi 2 a AWARE-1 ​​okhawo omwe amalembetsa odwala omwe ali ndi matenda a HR+/HER2-, subtype ya khansa ya m'mawere yomwe Oncolytics ikufuna kuunika mu kafukufuku wolembetsa wamtsogolo. Zotsatira zomwe zidanenedwa m'mbuyomu zidawonetsa kuti AWARE-1 ​​idakumana ndi mathero ake omasulira, gulu 2 likukwaniritsa njira zopambana zomwe zidanenedweratu pakuwonjezeka kwamankhwala kwa CelTIL (ulalo ku PR). CelTIL mphambu ndi metric ya kutupa kwa chotupa ndi ma cellular ndipo imalumikizidwa ndi zotsatira zabwino zachipatala mwa odwala khansa ya m'mawere.

"Zomwe zaposachedwa kwambiri zochokera ku AWARE-1 ​​zikuwonetsanso kuthekera kwa pelareorep kupititsa patsogolo zotsatira zachipatala mwa odwala khansa ya m'mawere kudzera pakutha kuyambitsa ma T cell ndikukonzanso chotupacho," atero a Thomas Heineman, MD, Ph.D., Chief Medical Officer wa Oncolytics. . "Chodziwika bwino, chithandizo cha pelareorep chinachulukitsa zizindikiro za kufa kwa maselo otupa ndipo, mwinanso chochititsa chidwi kwambiri, 100% ya odwala omwe amachiritsidwa ndi pelareorep anali ndi chiopsezo chowonjezereka cha Recurrence Score (ROR-S) poyerekeza ndi 55% poyambira. Pamodzi, zotsatira zaposachedwa za AWARE-1 ​​izi zimatsimikiziranso kuthekera kwa pelareorep kuukira zotupa kudzera munjira zingapo. ”